EP0044453A2 - New benzisoselenazolones, process for producing the same and pharmaceutical preparations containing the same - Google Patents
New benzisoselenazolones, process for producing the same and pharmaceutical preparations containing the same Download PDFInfo
- Publication number
- EP0044453A2 EP0044453A2 EP81105202A EP81105202A EP0044453A2 EP 0044453 A2 EP0044453 A2 EP 0044453A2 EP 81105202 A EP81105202 A EP 81105202A EP 81105202 A EP81105202 A EP 81105202A EP 0044453 A2 EP0044453 A2 EP 0044453A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- formula
- general formula
- hydrogen
- methylseleno
- benzisoselenazolones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C1)(C2)*3(CCCC3)C1(*)CCC(CC(C)=O)C2SC Chemical compound CC(C1)(C2)*3(CCCC3)C1(*)CCC(CC(C)=O)C2SC 0.000 description 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
- C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
- C07D421/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C391/00—Compounds containing selenium
- C07C391/02—Compounds containing selenium having selenium atoms bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
- C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D293/12—Selenazoles; Hydrogenated selenazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
- C07D517/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains two hetero rings
- C07D517/04—Ortho-condensed systems
Definitions
- the present invention is related to new benzisoselenazolones, process for producing the same, new intermediary products in their production as well as to the use of such new benzisoselenazolones as active agents in pharmaceutical preparations, in particular in anti-inflammatory and anti-rheumatic drugs.
- the benzisoselenazolones according to the present invention correspond to the general formula I wherein R 1 and R 2 which may be the same or different from each other, represent hydrogen, fluorine, chlorine, bromine, C 1 to 4 -alkyl such as methyl or ethyl; C 1 to 4-alkoxy such as methoxy; hydroxy, trifluoromethyl or nitro or, two neighbouring substituents together, i.e.
- R 1 and R 2 together represent the methylenedioxy group -O-CH 2 -0-
- R 3 and R 4 which may be the same or different from each other, represent hydrogen, fluorine, chlorine, bromine, C 1 to 4 -alkyl , C 1 to 4 -alkoxy , hydroxy, trifluoromethyl, nitro, di-(C 1 to 4 -alkyl)-amino or
- R 3 and R 4 together represent the methylenedioxy group -O-CH 2 -O- or R 3 is hydrogen with R 4 being -CN, -COOR 5 or R 5 being hydrogen, an alkali metal ion such as a potassium or in particular a sodium ion, or C 1 to 4 -alkyl and R 6 being hydrogen, methyl or ethyl, and n represents 0 or an integer from 1 to 4; from this definition there are excluded and disclaimed the known compounds 2-phenyl-, 2-o-tolyl- and 2-benzyl-1.2-benzisos
- the preferred compounds among the benzisoselenazolones of the general formula I are those wherein n is 0 and either R 1 and R 2 or R 1 and R 3 represent hydrogen while the other substituents (R 3 and R 4 or, respectively, R 2 and R 4 ) represent fluorine, chlorine, bromine, hydroxy, methoxy, methyl, trifluoromethyl and/or nitro.
- benzisoselenazolones of the general formula I are those wherein n is 0 or an integer from 1 to 4, R 1 , R 2 and R 3 represent hydrogen and R 4 is -CN, -COOR S or R 5 being H, N , -CH 3 or -C 2 H 5 and R 6 being H, -CH 3 or -C 2 H 5 ⁇
- Preferred substituents of the nitrogen atom of the isoselenazolonering in the compounds according to the present invention are for instance:
- the present invention is further related to new intermediary products for the production of the benzisoselenazolones of formula I.
- Such intermediary products correspond to the general formula II wherein R 1 to R 4 and n have the same meaning as in formula I.
- the benzisoselenazolones of formula I of the present invention may be used in the treatment of numerous diseases. For instance they are useful in the prophylactic treatment or cure of infectious diseases, for the therapeutical treatment of malign tumors, for the stimulation of the immunological system or in the treatment of selenium deficiency diseases as they are defined in W. KRAUSS and P. OEHME, Das Irish Gruscher 1979, vol. 34 (37), pgs. 1713 to 1718 and 1979, vol. 34 (37), pgs. 1769 to 1773.
- the benzisoselenazolones of formula I are however in particular characterized by their anti-arteriosclerotic and anti-inflammatory properties. They are therefor in particular useful in the therapy of rheumatic diseases such as arthroses or chronical polyarthritis.
- the new compounds are characterized by a very good compatibility since they have a low toxicity and, contrary to known anti-inflammatory agents, do not cause formation of ulcera or gastrointestinal irritations.
- the new compounds according to the present invention having the formula I surprisingly together with a very good anti-inflammatory activity show a substantially increased therapeutic range over the compounds known up to now in this field of application. Furthermore, they show no undesired side effects such as heartburn, formation of ulcera, intestinal bleedings and the like. They furthermore have a very low toxicity LD 2500 to 5000 mg./kg. (p.o. in mice or rats). This is all the more surprising since selenium compounds generally are considered as very toxic compounds.
- the new benzisoselenazolones of the present invention having the general formula I may be produced as follows:
- the embodiment a) of the present process corresponds in its process conditions to R. LESSER and R. WEISS, B er. 57 (1924), pgs. 1077 to 1082 and R. WEBER and M. RENSO N , Bull.Soc.Chim.France 1976 (7/8) pgs. 1124 to 1126.
- Starting compounds according to formula III may be for instance:
- the embodiment b) of the present process and its detailed process conditions correspond to-R. WEBER and M . RENSON, Bull. ' Soc. Chim. France 1976 (7/8), pgs. 1124 to 1126.
- the new intermediary products according to the present invention having the formula II may be obtained by subjecting a 2-methylseleno benzoic acid of general formula III to reaction with a dichloromethylalkylether, in particular a dichloromethyl lower alkyl ether and, in particular and therefor preferred, to reaction with dichloromethylmethylether and subjecting the resulting 2-methylseleno benzoic acid chloride of the general formula VII wherein R 1 and R 2 have the same meaning as in formula I, to reaction with an amine of the general formula V, possibly in the presence of an acid binding agent.
- the benzisoselenazolones according to the present invention having the general formula I may be furthermore produced by the embodiment c) of the present process using as inorganic acid chloride for instance and in particular phosphorus pentachloride.
- the benzisoselenazolones according to the present invention having the general formula I may be converted in usual manners to pharmaceutical preparations.
- the active agent of formula I may be used as such or in combination with suitable usual pharmaceutical diluents and/or carrier materials which are admixed as usual.
- suitable usual pharmaceutical diluents and/or carrier materials which are admixed as usual.
- the compounds according to the present application may be used in human and veterinary medicine in any usual form, for instance systemically, provided that the formation and upkeep of a sufficient blood or tissue level of the active agent is secured. This may be achieved with oral or rectal or parenteral administration at suitable dosages.
- the applied pharmaceutical preparation is for single dosage administration in accordance with the desired manner of administration, for instance as tablet, dragee, capsule, suppository, granulate, solution, emulsion, suspension, sol or gel.
- the compounds according to the present application in general are administered in dosages ranging from 10 to 1000 mg. per day, preferably from 30 to 300 mg. per day.
- the daily dose may be administered in a single dose or split into several dosages.
- the daily dose preferably is subdivided into two or three dosages per day.
- Suitable carrier materials which may be used in the preparation of pharamceutical products to be orally ad - ministered, for instance as tablets, capsules, granulates or powders, are for instance calcium carbonate, calcium phosphate, starch, sugar, lactose, talcum, magnesium stearate, gelatine, polyvinylpyrrolidone, gum arabic, sorbitol, microcristalline, cellulose, polyethyleneglycol, carboxymethyl cellulose, shellac and the like.
- the tablets may be coated in usual manners.
- Liquid products for oral application may be aqueous or oily suspensions or solutions, sirups, elixirs or the like. Such products are produced in usual manners.
- the new products according to the present invention having the general formula I may also be applied rectally as suppositories which further contain pharmaceutically acceptable carrier materials as they are known for this purpose,for instance polyethylene glycol, lanoline, coconut butter, Witepsol or the like.
- pharmaceutically acceptable carrier materials for instance polyethylene glycol, lanoline, coconut butter, Witepsol or the like.
- External pharmaceutical preparations are preferably produced as ointments or cremes in usual manners using usual components.
- o-Chloroselenobenzoic acid chloride was obtained by reacting o-methylselenobenzoic acid with thionylchloride as described in A. RUWET and M . RENSO N , Bull. Soc. Chim. Belg. 1966, vol. 75, pgs. 157 to 168.
- 2-(3-hydroxyphenyl)-1.2-benzisoselenazol-3(2H)-one is produced from 5.1 g. of o-chloroselenobenzoic acid chloride and 6.8 g. of 3-hydroxyaniline.
- 6-benzyloxy-2-phenyl-1.2-benzisoselenazol-3(2H)-one is produced from 5.95 g. of 4-benzyloxy-2-methylselenobenzoic acid anilide and 6.2 g. phosphorus pentachloride. Yield: 2.45 g. (43 % of the theoretical). F.p.: 198°C.
- 5-benzyloxy-2-phenyl-1.2-benzisoselenazol-3(2H)-one is produced by reacting 4.1 g. of 5-benzyloxy-2-methylselenobenzoic acid anilide and 4.3 g. of phosphorus pentachloride. Yield: 1.49 g. (38 % of the theoretical). F.p.: 143°C.
- 2-(4-Phenylbutyl)-1.2-benzisoselenazol-3(2H)-one is produced as described in Example 26 from 2 g. of N-(4-phenylbutyl)-2-methylselenobenzoic. acid amide and 0.92 g. of bromine. Yield: 1.26 g. (66 % of the theoretical). F.p.: 97 to 99°C.
- 5-Nitro-2-phenyl-1.2-benzisoselenazol-3(2H)-one is produced as described in Example 27 from 1.2 g. of N-phenyl-5-nitro-2-methylselenobenzoic acid amide and 0.57 g. of bromine. Yield: 0.81 g. (71 % of the theoretical). F.p.: 273°C.
- the above ingredients are mixed and pressed to tablets in usual manner using usual equipment. If desired,the resulting tablets may be coated with a usual coating.
- the resulting ingredients are mixed and pressed in usual manners using usual equipment. If desired, the resulting tablets may be coated with a usual coating.
- the resulting ingredients are mixed and pressed in usual manners usinf usual equipment. If desired, the resulting tablets may be coated with a usual coating.
- the above ingredients are mixed, granulated and filled into hard gelatine capsules in usual manners using usual equipment.
- the above ingredients are mixed, granulated and filled into hard gelatine capsules in usual manners using usual equipment.
- the above ingredients are mixed, granulated and filled into hard gelatine capsules in usual manners using usual equipmento.
Abstract
Description
- The present invention is related to new benzisoselenazolones, process for producing the same, new intermediary products in their production as well as to the use of such new benzisoselenazolones as active agents in pharmaceutical preparations, in particular in anti-inflammatory and anti-rheumatic drugs.
- The benzisoselenazolones according to the present invention correspond to the general formula I
- The preferred compounds among the benzisoselenazolones of the general formula I are those wherein n is 0 and either R1 and R2 or R1 and R3 represent hydrogen while the other substituents (R3 and R4 or, respectively, R2 and R4) represent fluorine, chlorine, bromine, hydroxy, methoxy, methyl, trifluoromethyl and/or nitro.
-
- Preferred substituents of the nitrogen atom of the isoselenazolonering in the compounds according to the present invention are for instance:
- with n being 0: 4-fluorophenyl, 4-chlorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 4-methylphenyl, 4-trifluoromethylphenyl, 4-nitrophenyl, 4-dimethylaminophenyl, 3-bromo-4-hydroxy-phenyl, 3.4-methylenedioxyphenyl, 2-hydroxyphenyl, 3-hydroxyphenyl, 2-fluorophenyl and 3-methoxyphenyl; with n different from 0: 2-(4-fluorophenyl)-ethyl, 4-phenylbutyl, 3-phenylpropyl, 2-phenylethyl and 4-(4-chlorophenyl)-butyl; with n being 0 and R3 being hydrogen: 4-hydroxycarbonyl- phenyl, 4-ethoxycarbonylphenyl, 4-hydroxycarbonylmethyl- phenyl, 4-ethoxycarbonylmethylphenyl, 4-[1-(hydroxycarbonyl) -ethyl]-phenyl, 4-[1- (ethoxycarbonyl) -ethyl]-phenyl and 4-cyanophenyl.
-
- The benzisoselenazolones of formula I of the present invention may be used in the treatment of numerous diseases. For instance they are useful in the prophylactic treatment or cure of infectious diseases, for the therapeutical treatment of malign tumors, for the stimulation of the immunological system or in the treatment of selenium deficiency diseases as they are defined in W. KRAUSS and P. OEHME, Das Deutsche Gesundheitswesen 1979, vol. 34 (37), pgs. 1713 to 1718 and 1979, vol. 34 (37), pgs. 1769 to 1773.
- The benzisoselenazolones of formula I are however in particular characterized by their anti-arteriosclerotic and anti-inflammatory properties. They are therefor in particular useful in the therapy of rheumatic diseases such as arthroses or chronical polyarthritis. The new compounds are characterized by a very good compatibility since they have a low toxicity and, contrary to known anti-inflammatory agents, do not cause formation of ulcera or gastrointestinal irritations.
- The new compounds according to the present invention having the formula I surprisingly together with a very good anti-inflammatory activity show a substantially increased therapeutic range over the compounds known up to now in this field of application. Furthermore, they show no undesired side effects such as heartburn, formation of ulcera, intestinal bleedings and the like. They furthermore have a very low toxicity LD 2500 to 5000 mg./kg. (p.o. in mice or rats). This is all the more surprising since selenium compounds generally are considered as very toxic compounds.
- The new benzisoselenazolones of the present invention having the general formula I may be produced as follows:
- a) a 2-methylseleno-benzoic acid having the general formula III
- b) a 2-methylseleno-benzamide having the general formula II is : subjected to ring closure in the presence of an inorganic acid chloride to yield a 3-chloro-1.2-benzisoselenazolonium compound having the general formula VI
- c) a 2-methylseleno-benzamide having the general formula II is subjected to reaction with bromine and thereafter is heated, possibly in the presence of an organic acid or base,
- The embodiment a) of the present process corresponds in its process conditions to R. LESSER and R. WEISS, Ber. 57 (1924), pgs. 1077 to 1082 and R. WEBER and M. RENSON, Bull.Soc.Chim.France 1976 (7/8) pgs. 1124 to 1126. Starting compounds according to formula III may be for instance:
- 2-Methylseleno benzoic acid
- 2-Methylseleno-4-methyl benzoic acid
- 2-Methylseleno-4-fluoro benzoic acid
- 2-Methylseleno-4-chloro benzoic acid
- 2-Methylseleno-4-methoxy benzoic acid
- 2-Methylseleno-5-nitro benzoic acid
- 2-Methylseleno-5-chloro benzoic acid
- 2-Methylseleno-3-methoxy benzoic acid
- 2-Methylseleno-4-trifluoromethyl benzoic acid
- 2-Methylseleno-5-methoxy benzoic acid
- 2-Methylseleno-6-methoxy benzoic acid
- 2-Methylseleno-4.5-dichloro benzoic acid
- 2-Methylseleno-3.4-methylenedioxy benzoic acid
- 2-Methylseleno-3.4-dimethyl benzoic acid
- 2-Methylseleno-3.4-dichloro benzoic acid
- The embodiment b) of the present process and its detailed process conditions correspond to-R. WEBER and M. RENSON, Bull.'Soc. Chim. France 1976 (7/8), pgs. 1124 to 1126.
- The new intermediary products according to the present invention having the formula II may be obtained by subjecting a 2-methylseleno benzoic acid of general formula III to reaction with a dichloromethylalkylether, in particular a dichloromethyl lower alkyl ether and, in particular and therefor preferred, to reaction with dichloromethylmethylether and subjecting the resulting 2-methylseleno benzoic acid chloride of the general formula VII
- The benzisoselenazolones according to the present invention having the general formula I may be furthermore produced by the embodiment c) of the present process using as inorganic acid chloride for instance and in particular phosphorus pentachloride.
- The benzisoselenazolones according to the present invention having the general formula I may be converted in usual manners to pharmaceutical preparations. For instance, the active agent of formula I may be used as such or in combination with suitable usual pharmaceutical diluents and/or carrier materials which are admixed as usual. The compounds according to the present application may be used in human and veterinary medicine in any usual form, for instance systemically, provided that the formation and upkeep of a sufficient blood or tissue level of the active agent is secured. This may be achieved with oral or rectal or parenteral administration at suitable dosages. Preferably, the applied pharmaceutical preparation is for single dosage administration in accordance with the desired manner of administration, for instance as tablet, dragee, capsule, suppository, granulate, solution, emulsion, suspension, sol or gel. The compounds according to the present application in general are administered in dosages ranging from 10 to 1000 mg. per day, preferably from 30 to 300 mg. per day. The daily dose may be administered in a single dose or split into several dosages. The daily dose preferably is subdivided into two or three dosages per day.
- Suitable carrier materials which may be used in the preparation of pharamceutical products to be orally ad- ministered, for instance as tablets, capsules, granulates or powders, are for instance calcium carbonate, calcium phosphate, starch, sugar, lactose, talcum, magnesium stearate, gelatine, polyvinylpyrrolidone, gum arabic, sorbitol, microcristalline, cellulose, polyethyleneglycol, carboxymethyl cellulose, shellac and the like. The tablets may be coated in usual manners. Liquid products for oral application may be aqueous or oily suspensions or solutions, sirups, elixirs or the like. Such products are produced in usual manners. For administration by injection there may be used aqueous or oily suspensions or solutions, powderous products admixed with a filler or lyophilised products which are dissolved before administration. Such products are produced in usual manner.
- The new products according to the present invention having the general formula I may also be applied rectally as suppositories which further contain pharmaceutically acceptable carrier materials as they are known for this purpose,for instance polyethylene glycol, lanoline, coconut butter, Witepsol or the like. External pharmaceutical preparations are preferably produced as ointments or cremes in usual manners using usual components.
- The following Examples serve to further illustrate the present invention without however limiting the same thereto.
-
- 5.54 g. of p-toluidine dissolved in 100 cc. of carbontetrachloride are added dropwise with stirring and ice-cooling (temperature below 10°C.) under a nitrogen atmosphere to a solution of 4 g. of o-chloroselenobenzoic acid chloride dissolved in 80 cc. of carbontetrachloride. After termination of the addition stirring is continued for one hour. The resulting precipitate is filtered off, consecutively washed with a small amount of carbontetrachloride, 0.5 N-hydrochloric acid and water, thereafter is dried and then is recrystallized from carbontetrachloride.
- Yield: 4.0 g. (90 % of the theoretical). F.p.: 173 to 174°C.
- o-Chloroselenobenzoic acid chloride was obtained by reacting o-methylselenobenzoic acid with thionylchloride as described in A. RUWET and M. RENSON, Bull. Soc. Chim. Belg. 1966, vol. 75, pgs. 157 to 168.
-
-
- A solution of 2.8 g. of 4-dimethylaminoaniline and 3.2 g. of triethylamine in 60 cc. of carbontetrachloride are added dropwise with stirring and ice cooling (temperature below 10°C.) under a nitrogen atmosphere to a solution of 3.82 g. of o-chloroselenobenzoic acid chloride in 30 cc. of carbontetrachloride. After termination of the addition, stirring is continued for another hour at room temperature. The resulting precipitate is filtered off, dried and stirred with a small amount of water. The insoluble crude final product is recrystallized from toluene/hexane.
- Yield: 2.8 g. (59 % of the theoretical). F.p.: 220 to 222 o C.
-
- 4.58 g. of 4-aminophenol dissolved in 200 cc. of tetrahydrofurane (THF) and 2 cc. of pyridine are added with stirring and ice-cooling (temperature below 10°C.) under a nitrogen atmosphere to a solution of 3.3 g. of o-chloroselenobenzoic. acid chloride in 30 cc. of THF. After termination of the addition, the mixture is stirred at room temperatur, the solvent is evaporated under vacuum and the residue is pured into a mixture of ice and dilute hydrochloric acid.The resulting precipitate is filtered off and is recrystallized from ethanol.
- Yield: 2.3 g. (61 % of the theoretical).
- F.p.: 253 to 254°C.
-
- As described in Example 14, 2-(3-hydroxyphenyl)-1.2-benzisoselenazol-3(2H)-one is produced from 5.1 g. of o-chloroselenobenzoic acid chloride and 6.8 g. of 3-hydroxyaniline.
- Yield: 2.5 g. (43 % of the theoretical).
- F.p.: 195 to 197°C.
-
- As described in Example 14, 2-(2-hydroxyphenyl)-1.2-benzisoselenazol-3(2H)-one is produced from 2 g. of o-chloroselenobenzoic acid chloride and 2.7 g. of 2-hydroaniline. Yield: 0.91 g. (40 % of the theoretical). F.p.: 194 to 196°C.
-
- 3.09 g. of 4-fluoro-2-methylselenobenzoic.acid anilide are added dropwise with vivid stirring to a suspension of 4.16 g. of phosphorus pentachloride in 100 cc. of toluene. After termination of the addition, the resulting mixture is refluxed for two hours and thereafter is evaporated in a vacuum. The residue is triturated with anhydrous ethanol at 0°C. The resulting 3-chloro-6-fluoro-2-phenyl-1.2-benzisoselenazolium chloride is filtered off, suspended in a mixture of 20 cc. of water and 60 cc. of alcohol and heated to 70°C. until fully dissolved. The resulting solution is refluxed for one hour, thereafter evaporated and the resulting precipitate is filtered off and recrystallized from benzene/toluene. Yield: 1.67 g. (57 % of the theoretical). F.p.: 220°C.
-
-
- As described in Example 17, 6-benzyloxy-2-phenyl-1.2-benzisoselenazol-3(2H)-one is produced from 5.95 g. of 4-benzyloxy-2-methylselenobenzoic acid anilide and 6.2 g. phosphorus pentachloride. Yield: 2.45 g. (43 % of the theoretical). F.p.: 198°C.
- As described in J.P. GREENSTEIN and M. WINITZ, Chemistry of the Amino Acids (1961), p. 2736, the benzyl group in this compound is split off with hydrogen in the presence of palladium and the resulting product is recrystallized from ethanol.
Yield: 16 g. (62 % of the theoretical). F:p.: 235°C. -
- As described in Example 17, 5-benzyloxy-2-phenyl-1.2-benzisoselenazol-3(2H)-one is produced by reacting 4.1 g. of 5-benzyloxy-2-methylselenobenzoic acid anilide and 4.3 g. of phosphorus pentachloride. Yield: 1.49 g. (38 % of the theoretical). F.p.: 143°C.
- As described in Example 25, the benzyl group is split off from this compound. The resulting product is recrystallized from ethanol.
Yield: 0.49 g. (43 % of the theoretical). F.p.: 192°C. -
- A solution of 0.44 g. of bromine in 10 cc. of dichloromethane are added dropwise at O°C, under a nitrogen atmosphere to a solution of 1 g. of N-(4-trifluoromethylphenyl)-2-methylselenobenzoic acid amide in 40 cc. of dichloromethane. After termination of the addition, stirring is contiued at room temperature for 30 minutes and the reaction mixture is evaporated under vacuum at 30oC. The resulting residue is mixed with 50 cc. of anhydrous acetic acid, the mixture refluxed for three hours and thereafter mixed with ice-water. The resulting precipitate is filtered off with suction and is recrystallized from ethanol/toluene.
Yield: 0.8 g. (84 % of the theoretical). F.p.: 246 to 248°C. -
- A solution of 0.88 g. of bromine in 10 cc. of dichloromethane is added dropwise at O°C, under a nitrogen atmosphere to a solution of 1.76 g. of N-phenyl-4-methoxy-2-methylselenobenzoic acid amide in 40 cc. of dichloromethane. After termination of the addition, the mixture is stirred for 30 minutes. The resulting precipitate is filtered off with suction and mixed with 20 cc. of pyridine. This mixture is refluxed for three hours and mixed with ice-water. The resulting crude material is recrystallized from ethanol/benzene.
Yield: 1.2 g. (72 % of the theoretical) . F.p.: 189°C. -
- 2-(4-Phenylbutyl)-1.2-benzisoselenazol-3(2H)-one is produced as described in Example 26 from 2 g. of N-(4-phenylbutyl)-2-methylselenobenzoic. acid amide and 0.92 g. of bromine.
Yield: 1.26 g. (66 % of the theoretical). F.p.: 97 to 99°C. -
-
- A solution of 0.53 g. of bromine in 500 cc. of acetic acid is added dropwise at room temperature under a nitrogen atmosphere to a solution of 1 g. of N-(4-hydroxyphenyl)-2-methylselenobenzoic acid amide in 40 cc. of acetic acid. After termination of the addition, stirring is continued at room temperature for one hour, the mixture is refluxed for two hours and thereafter is mixed with ice-water. The resulting precipitate is filtered off and is recrystallized from ethanol/benzene.
Yield: 0.58 g. (48 % of the theoretical). F.p.: 232 to 234°C. -
- 11.725 g. of 2-Methylselenobenzoic acid and 0.1 g. of anhydrous zinc-II-chloride are suspended in 50 cc. of dichloromethane and 9.2 g. of α,α -dichloromethylether are added dropwise thereto. After one hour the resulting clear solution is evaporated in a vacuum, the oily residue is dissolved in carbontetrachloride, filtered with activated carbon and evaporated. The resulting 2-methylselenobenzoic acid chloride is dissolved in 50 cc. of tetrahydrofurane and added dropwise with ice- cooling to a solution of 8.86 g. of 4-trifluoromethylaniline in 70 cc. of tetrahydrofurane and 6 g. of triethylamine. The mixture is stored at room temperature for ten hours and thereafter is mixed with ice and dilute hydrochloric acid. The resulting precipitate is filtered off, dried and recrystallized from toluene/ hexane.
Yield: 9.06 g. (82 % of the theoretical). F.p.: 174 to 176°C. -
-
- The above ingredients are mixed and pressed to tablets in usual manner using usual equipment. If desired,the resulting tablets may be coated with a usual coating.
-
- The resulting ingredients are mixed and pressed in usual manners using usual equipment. If desired, the resulting tablets may be coated with a usual coating.
-
- The resulting ingredients are mixed and pressed in usual manners usinf usual equipment. If desired, the resulting tablets may be coated with a usual coating.
-
-
-
- The above ingredients are mixed, granulated and filled into hard gelatine capsules in usual manners using usual equipment.
-
- The above ingredients are mixed, granulated and filled into hard gelatine capsules in usual manners using usual equipment.
-
- The above ingredients are mixed, granulated and filled into hard gelatine capsules in usual manners using usual equipmento.
and the resulting benzisoselenazolone of formula I finally is separated from the reaction mixture.
Claims (6)
and the resulting benzisoselenazolone of formula I is separated from the reaction mixture.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT81105202T ATE7029T1 (en) | 1980-07-17 | 1981-07-04 | BENZISOSELENAZOLONE, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM. |
AT83104535T ATE17118T1 (en) | 1980-07-17 | 1981-07-04 | 2-METHYLSELENO-BENZAMIDE. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19803027075 DE3027075A1 (en) | 1980-07-17 | 1980-07-17 | BENZISOSELENAZOLONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
DE3027075 | 1980-07-17 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP83104535A Division-Into EP0098934B1 (en) | 1980-07-17 | 1981-07-04 | 2-methylseleno-benzamides |
EP83104535A Division EP0098934B1 (en) | 1980-07-17 | 1981-07-04 | 2-methylseleno-benzamides |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0044453A2 true EP0044453A2 (en) | 1982-01-27 |
EP0044453A3 EP0044453A3 (en) | 1982-03-31 |
EP0044453B1 EP0044453B1 (en) | 1984-04-11 |
Family
ID=6107417
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP81105202A Expired EP0044453B1 (en) | 1980-07-17 | 1981-07-04 | New benzisoselenazolones, process for producing the same and pharmaceutical preparations containing the same |
EP83104535A Expired EP0098934B1 (en) | 1980-07-17 | 1981-07-04 | 2-methylseleno-benzamides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP83104535A Expired EP0098934B1 (en) | 1980-07-17 | 1981-07-04 | 2-methylseleno-benzamides |
Country Status (8)
Country | Link |
---|---|
US (1) | US4418069A (en) |
EP (2) | EP0044453B1 (en) |
JP (1) | JPS5767568A (en) |
CA (1) | CA1168243A (en) |
DE (1) | DE3027075A1 (en) |
DK (1) | DK150903C (en) |
IE (1) | IE51344B1 (en) |
ZA (1) | ZA814606B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0100899A2 (en) * | 1982-07-14 | 1984-02-22 | A. Nattermann & Cie. GmbH | Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them |
EP0100898A1 (en) * | 1982-07-14 | 1984-02-22 | A. Nattermann & Cie. GmbH | Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them |
EP0154851A1 (en) * | 1984-03-01 | 1985-09-18 | A. Nattermann & Cie. GmbH | Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds |
EP0257306A1 (en) * | 1986-08-06 | 1988-03-02 | A. Nattermann & Cie. GmbH | Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and pharmaceutical compounds comprising the same |
US4778814A (en) * | 1987-03-18 | 1988-10-18 | Ciba-Geigy Corporation | Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one |
US4778815A (en) * | 1987-03-18 | 1988-10-18 | Ciba-Geigy Corporation | Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one |
EP0729756A1 (en) * | 1992-04-28 | 1996-09-04 | Daiichi Pharmaceutical Co., Ltd. | Granular preparation |
WO2000001380A1 (en) * | 1998-07-01 | 2000-01-13 | A. Nattermann & Cie. Gmbh | cyclo-oxygenase inhibitor |
US6335036B1 (en) | 1993-10-27 | 2002-01-01 | Daiichi Pharmaceutical Co., Ltd. | Granular pharmaceutical preparation of ebselen |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3027075A1 (en) | 1980-07-17 | 1982-02-18 | A. Nattermann & Cie GmbH, 5000 Köln | BENZISOSELENAZOLONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
DE3568775D1 (en) * | 1984-06-22 | 1989-04-20 | Nattermann A & Cie | S-(carbamoyl-phenylselenyl) derivatives of glutathion and of amino mercaptocarboxylic acids, process for their preparation and pharmaceutical preparations containing them |
DE3443467A1 (en) * | 1984-11-29 | 1986-05-28 | A. Nattermann & Cie GmbH, 5000 Köln | MERCAPTAN DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
DE3444135A1 (en) * | 1984-12-04 | 1986-06-05 | A. Nattermann & Cie GmbH, 5000 Köln | Selenoxides, process for their preparation and pharmaceutical preparations containing them |
EP0198277B1 (en) * | 1985-04-12 | 1989-05-03 | A. Nattermann & Cie. GmbH | Diseleno-bis-benzamides of primary and secondary amines, processes for their production and pharmaceutical preparations containing them |
DE3670635D1 (en) * | 1985-04-27 | 1990-05-31 | Nattermann A & Cie | NEW BENZISOSELENAZOLONYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM. |
DE3718765A1 (en) * | 1986-06-11 | 1987-12-17 | Nippon Shinyaku Co Ltd | BENZOESAEUR DERIVATIVES |
DE3937169A1 (en) * | 1989-11-08 | 1991-05-16 | Nattermann A & Cie | BENZYLSELENOBENZAMIDES OF ANILINE AND BENZYLAMINE |
DE3937170A1 (en) * | 1989-11-08 | 1991-05-16 | Nattermann A & Cie | BENZYLSELENOBENZAMIDES OF AMINOPYRIDINES AND PICOLYLAMINES |
AU5513796A (en) * | 1995-04-25 | 1996-11-18 | Daiichi Pharmaceutical Co., Ltd. | Remedy for acquired immunodeficiency syndrome |
AU3457300A (en) * | 1999-03-31 | 2000-10-16 | Daiichi Pharmaceutical Co., Ltd. | Substrates for thioredoxin reductase |
CN1166651C (en) * | 2001-06-08 | 2004-09-15 | 北京大学药学院 | Anti-inflammatory and antineoplastic R-bis or glycophenylpropane isoselenazole substituted compound |
US10058542B1 (en) | 2014-09-12 | 2018-08-28 | Thioredoxin Systems Ab | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR6429M (en) | 1966-01-05 | 1968-11-04 | ||
CA1112164A (en) * | 1977-08-02 | 1981-11-10 | Joseph R. Levitt | Therapeutic selenium compositions and the use thereof |
DE3027075A1 (en) | 1980-07-17 | 1982-02-18 | A. Nattermann & Cie GmbH, 5000 Köln | BENZISOSELENAZOLONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
DE3027074A1 (en) * | 1980-07-17 | 1982-02-18 | A. Nattermann & Cie GmbH, 5000 Köln | Benz-iso selenazolone derivs. as antiinflammatories - esp. for treating rheumatic illnesses, causing no ulcer formation or gastrointestinal irritation |
-
1980
- 1980-07-17 DE DE19803027075 patent/DE3027075A1/en active Granted
-
1981
- 1981-07-04 EP EP81105202A patent/EP0044453B1/en not_active Expired
- 1981-07-04 EP EP83104535A patent/EP0098934B1/en not_active Expired
- 1981-07-06 IE IE1513/81A patent/IE51344B1/en not_active IP Right Cessation
- 1981-07-07 ZA ZA814606A patent/ZA814606B/en unknown
- 1981-07-09 US US06/281,719 patent/US4418069A/en not_active Expired - Lifetime
- 1981-07-16 JP JP56112076A patent/JPS5767568A/en active Granted
- 1981-07-16 CA CA000381895A patent/CA1168243A/en not_active Expired
- 1981-07-16 DK DK319281A patent/DK150903C/en not_active IP Right Cessation
Non-Patent Citations (2)
Title |
---|
BERICHTE DER DEUTSCHEN CHEMISCHEN GESELLSCHAFT, vol. 57, no. 7, July 9, 1924, Berlin, DE; R. LESSER and K. WEISZ: "Uber selenhaltige aromatische Verbindungen ", pages 1077-1081 * |
BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, vol. 7-8, July-August 1976, Paris, FR; R. WEBER and M. RENSON: " Les chlorures de chloro-3 benzisosélénazolium-1,2:synthèse, hydrolyse, thiolation ammonolyse ", pages 1124-1126 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0100899A2 (en) * | 1982-07-14 | 1984-02-22 | A. Nattermann & Cie. GmbH | Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them |
EP0100898A1 (en) * | 1982-07-14 | 1984-02-22 | A. Nattermann & Cie. GmbH | Cycloalkyl derivatives of benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them |
EP0100899A3 (en) * | 1982-07-14 | 1985-07-17 | A. Nattermann & Cie. Gmbh | Benzisoselenazolones, process for their preparation and pharmaceutical compositions containing them |
EP0154851A1 (en) * | 1984-03-01 | 1985-09-18 | A. Nattermann & Cie. GmbH | Benzisoselenazolethiones,process for their preparation and pharmaceutical products containing these compounds |
EP0257306A1 (en) * | 1986-08-06 | 1988-03-02 | A. Nattermann & Cie. GmbH | Diselenobis benzoic acid amides of primary heterocyclic amines, process for producing the same and pharmaceutical compounds comprising the same |
US4778815A (en) * | 1987-03-18 | 1988-10-18 | Ciba-Geigy Corporation | Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one |
US4778814A (en) * | 1987-03-18 | 1988-10-18 | Ciba-Geigy Corporation | Method of treating ocular allergy by topical application of a 2-substituted-1,2-benzisoselenazol-3(2H)-one |
EP0729756A1 (en) * | 1992-04-28 | 1996-09-04 | Daiichi Pharmaceutical Co., Ltd. | Granular preparation |
EP0729756A4 (en) * | 1992-04-28 | 1997-07-02 | Daiichi Seiyaku Co | Granular preparation |
US6335036B1 (en) | 1993-10-27 | 2002-01-01 | Daiichi Pharmaceutical Co., Ltd. | Granular pharmaceutical preparation of ebselen |
WO2000001380A1 (en) * | 1998-07-01 | 2000-01-13 | A. Nattermann & Cie. Gmbh | cyclo-oxygenase inhibitor |
EP0972515A2 (en) * | 1998-07-01 | 2000-01-19 | A. Nattermann & Cie. GmbH | Cyclooxygenase Inhibitor |
EP0972515A3 (en) * | 1998-07-01 | 2000-01-26 | A. Nattermann & Cie. GmbH | Cyclooxygenase Inhibitor |
US6495517B2 (en) | 1998-07-01 | 2002-12-17 | A. Natterman & Cie. Gmbh | Cyclooxygenase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
JPS5767568A (en) | 1982-04-24 |
EP0044453B1 (en) | 1984-04-11 |
DE3027075C2 (en) | 1989-05-18 |
ZA814606B (en) | 1982-07-28 |
JPH0238591B2 (en) | 1990-08-31 |
DE3027075A1 (en) | 1982-02-18 |
DK319281A (en) | 1982-01-18 |
DK150903B (en) | 1987-07-13 |
EP0098934A1 (en) | 1984-01-25 |
US4418069A (en) | 1983-11-29 |
DK150903C (en) | 1988-01-25 |
IE51344B1 (en) | 1986-12-10 |
EP0098934B1 (en) | 1985-12-27 |
IE811513L (en) | 1982-01-17 |
EP0044453A3 (en) | 1982-03-31 |
CA1168243A (en) | 1984-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0044453B1 (en) | New benzisoselenazolones, process for producing the same and pharmaceutical preparations containing the same | |
CA1336913C (en) | Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase | |
JPS5936988B2 (en) | New aminothiazoles | |
HU184966B (en) | Process for producing phenyl-piperazine derivatives of anti-agression activity | |
CS216544B2 (en) | Method of preparation of basic ethers | |
US3975531A (en) | 4-(5- And 7-)benzoylindolin-2-ones and pharmaceutical uses thereof | |
JPH02157273A (en) | Arylalkoxycoumarine, production thereof, and remedy | |
JPS6028979A (en) | Imidazoquinazoline compound | |
US5110831A (en) | Vinylogous hydroxamic acids and derivatives thereof as 5-lipoxygenase inhibitors | |
JPH01294670A (en) | 2-(piperadinyl)-2-oxoethylene-substituted flavonoid derivative, its production and pharmaceutical composition containing said derivative | |
JPS6117574A (en) | Calcium-antagonistic 1-(bis-(4-fluorophenyl)-methyl)-4- (3-phenyl-2-propenyl)-hexahydro-1h-1,4-diazepine, manufacture and medicinal composition | |
CA1128512A (en) | 2-amino-3-benzoyl-phenylacetamides and cyclic homologues | |
JPS6399057A (en) | Glycine derivative | |
JPS6310777A (en) | Piperazineacetamide derivative | |
JPS6056130B2 (en) | Novel salicylic acid derivatives | |
US4743605A (en) | Saturated fatty acid amides as inhibitors of acyl-coa:cholesterol acyltransferase | |
EP0047358B1 (en) | Indol acetic derivatives, process for producing the same and pharmaceutical compositions comprising the same | |
US4464379A (en) | Indol acetic acid derivatives and anti-inflamatory and related uses thereof | |
EP0045473B1 (en) | A pharmaceutical composition containing a benzofuran-carboxamide derivative as the active ingredient | |
JPH02233677A (en) | New 1-(3-(2-hydroxy-3-alkylaminopropoxy)-2-thienyl)- 3-phenyl-1-propanone,and preparation thereof | |
US3652584A (en) | 1 3-di-aryl-1 2-pyrazolines and their preparation | |
KR840001967B1 (en) | Process for the 1,1,3,5-substituted biuret compound | |
US3192110A (en) | Therapeutic aryl and thienyl hydroxylamines | |
US3891699A (en) | Biphenylenealkanoic acids | |
JPS6168490A (en) | 1,3-dihydro-6-aminomethyl-7-hydroxy-furo-(3,4-c)-pyridine derivative, manufacture and medicinal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH FR GB IT LI LU NL SE |
|
AK | Designated contracting states |
Designated state(s): AT BE CH FR GB IT LI LU NL SE |
|
17P | Request for examination filed |
Effective date: 19820910 |
|
ITF | It: translation for a ep patent filed |
Owner name: ING. C. GREGORJ S.P.A. |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH FR GB IT LI LU NL SE |
|
REF | Corresponds to: |
Ref document number: 7029 Country of ref document: AT Date of ref document: 19840415 Kind code of ref document: T |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
ITTA | It: last paid annual fee | ||
EPTA | Lu: last paid annual fee | ||
EAL | Se: european patent in force in sweden |
Ref document number: 81105202.6 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19990628 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19990630 Year of fee payment: 19 Ref country code: FR Payment date: 19990630 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19990705 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 19990715 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 19990723 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19990730 Year of fee payment: 19 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19991022 Year of fee payment: 19 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000704 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000704 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000704 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000705 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000731 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000731 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000731 |
|
BERE | Be: lapsed |
Owner name: A. NATTERMANN & CIE G.M.B.H. Effective date: 20000731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010201 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20000704 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed |
Ref document number: 81105202.6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010330 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20010201 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |